share_log

Pasithea Stock Plunges After Equity Raise of $30M

Pasithea Stock Plunges After Equity Raise of $30M

Pasithea股票在股權融資3000萬美元后暴跌
Benzinga Real-time News ·  2021/11/24 13:00

Pasithea Therapeutics Corp (NASDAQ:KTTA) shares shed their gains from yesterday after it announced a private offering of 8.68 million shares and warrants to purchase 8.68 million shares.

帕西婭治療公司納斯達克(KTTA)股價昨日下跌，此前該公司宣佈私募868萬股和認股權證，購買868萬股。

  • The offer price of $3.50 per share represents a steep discount of 38% from the last close price of $5.60 that more than doubled on Tuesday.
  • Related Link: EXCLUSIVE: Pasithea's Depression Treatment, Esketamine Nasal Spray Added In Clinic Offerings In UK.
  • The gross proceeds are expected to be approximately $30.4 million.
  • The warrants will be immediately exercisable and have an exercise price of $3.50 per share. 
  • The warrants will expire five years from the date of issuance. 
  • The offering is expected to close by November 29.
  • Pasithea will use the proceeds to fund pre-clinical research and development work for future product candidates, invest in developing the US and the UK clinic businesses, and for working capital and general corporate purposes.
  • Price Action: KTTA shares are down 26.1% at $4.14 during the market session on the last check Wednesday.
  • 收購價為每股3.50美元，較週二上漲逾一倍的上一交易日收盤價5.60美元大幅折讓38%。
  • 相關鏈接： 獨家報道：Pasithea的抑鬱症治療，英國臨牀產品中增加了埃斯氯胺酮鼻腔噴霧劑.
  • 預計總收益約為3040萬美元。
  • 認股權證將立即可行使，行權價為每股3.50美元。
  • 權證將自發行之日起五年到期。
  • 此次發行預計將於11月29日完成。
  • Pasithea將利用所得資金為未來候選產品的臨牀前研究和開發工作提供資金，投資於發展美國和英國的診所業務，並用於營運資本和一般企業用途。
  • 價格行動：週三尾盤，KTTA股價下跌26.1%，至4.14美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論